Key result
Higher visceral adiposity index and lipid accumulation product link to elevated cardiometabolic risk in hypertension.
Why the study?
Arterial hypertension is a risk factor for cardiovascular diseases, prompting evaluation of the association between two adiposity indices and traditional markers of cardiometabolic risk in hypertensive patients.
Are visceral adiposity index and lipid accumulation product associated with traditional markers of cardiometabolic risk in patients with hypertension?
Cross-Sectional (n=1,273)
No
Are visceral adiposity index and lipid accumulation product associated with traditional markers of cardiometabolic risk in patients with hypertension?
p-value: p=≤0.05
Visceral adiposity index and lipid accumulation product correlate with traditional cardiometabolic risk markers in hypertensive patients, supporting their potential use in cardiovascular disease risk screening.
May support risk screening in hypertension; leaves open prospective validation before clinical adoption.
Objective: Arterial hypertension (AH) is a risk factor for cardiovascular diseases (CVD). We sought to evaluate the association between two adiposity indices (visceral adiposity index [VAI] and lipid accumulation product [LAP]) with traditional markers of cardiometabolic risk in hypertensive patients. Materials and methods: This is a cross-sectional study with 1,273 subjects with hypertension treated as outpatients at a university hospital. The VAI and LAP were calculated using formulas stratified by sex. Cardiometabolic risk variables were considered: overweight, risk for waist circumference (WC), waist-to-hip ratio (WHR), waist-to-height ratio (WHA), and altered biochemical test values. The predictive effect of independent variables on outcomes was assessed by multivariate linear regression analysis. There was statistical significance when p ≤ 0.05. Results: Higher cardiometabolic risk (according to BMI, WHR, WHA, and altered biochemical parameters) was associated with higher values of VAI and LAP with statistical significance (p ≤ 0.05). The regression models used explained 30.7% and 10.5% of the changes in LAP and VAI, respectively. Conclusion: LAP and VAI are associated with cardiometabolic risk parameters in the individuals evaluated, suggesting that these indices can be used to screen for CVD risk in individuals with AH.
No takes yet. Share an insight, caveat, or question.
Sena et al. (2022) conducted a cross-sectional in Arterial hypertension (n=1,273). Visceral adiposity index (VAI) and lipid accumulation product (LAP) was evaluated on Association with cardiometabolic risk markers (BMI, WHR, WHA, and altered biochemical parameters) (p=≤0.05). Higher values of visceral adiposity index and lipid accumulation product were significantly associated with higher cardiometabolic risk markers in patients with hypertension.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: